Introduction {#s1}
============

Glioblastoma multiforme (GBM) progresses by co-opting stromal cells that reside in or are recruited to the tumor microenvironment (TME), which is a complex ecosystem composed of heterogeneous tumor cells associated with extensive hypoxic zones, reactive astrocytes, and infiltrating distinct immune components, including microglia, tumor-associated macrophages (TAMs) derived from peripheral blood monocytes, granulocytes, myeloid-derived suppressor cells (MDSCs), and T cells ([@B1]--[@B5]). In particular, GBM tumor cells along with immune factors create a complex milieu, which ultimately leads to alteration of the tumor cell transcriptome and tumor evolution ([@B6], [@B7]). TAMs, the predominant immune population infiltrating GBMs ([@B1], [@B8]), orchestrates GBM evolution by facilitating the mesenchymal transition, neoangiogenesis, extra-cellular matrix remodeling, and immune modulation ([@B6], [@B9]--[@B11]). Furthermore, accumulation of CD4^+^ T helper (Th) cells and CD4^+^CD25^+^ transcription factor forkhead box P3 (FoxP3)^+^ regulatory T cells (Tregs) combined with the reduced presence of CD8^+^ cytotoxic T cells results in curtailment of immunotherapeutic efficacy ([@B9], [@B12]).

However, the nature of GBM-infiltrating γδ T cells has not been extensively investigated, although γδ T cells have the potential to kill cancer cells and to change the pro-tumoral TME to one favoring acute responses and potent anti-tumoral activity. ([@B13]--[@B19]). The human TCR variable (V) regions of TCR γ and δ genes contains 14 unique Vγ segments (TRGV), three unique Vδ segments (TRDV1, TRDV2, and TRDV3), and five Vδ segments that share a common nomenclature with Vα segments (TRDV4/TRAV14, TRDV5/TRAV29, TRDV6/TRAV23, TRDV7/TRAV36, and TRDV8/TRAV38-2) ([@B20]). In healthy human adults, circulating T lymphocytes include 1--3% γδ T cells, most of which are Vγ9Vδ2 T cells ([@B16]). Vγ9Vδ2 T cells are activated by pyrophosphate-containing metabolites, generically known as phosphoantigens (pAgs), which are derived from microbes or metabolically active tumor cells and bind to the intracellular domain of the butyrophilin-related molecule BTN3A1 without major histocompatibility complex (MHC)- or CD1-dependent antigen presentations ([@B18], [@B21]). Especially, isopentenyl pyrophosphate (IPP) is a pAg generated from the mevalonate pathway in mammalian cells ([@B22]), and Vγ9Vδ2 T cells have additional sensor for detecting cancer cells via recognition of IPP accumulated intracellularly during dysregulated metabolism in cancer cells ([@B16]--[@B18], [@B23]). GBM cancer cells also express several MHC-like stress-induced self-antigens (MIC-A/B), heat shock protein-60, U16-binding protein 4, human MutS homolog 2, and F1-ATP synthase, which are recognized by TCRs, Toll-like receptors, or natural killer (NK) receptors expressed on Vγ9Vδ2 T cells, triggering cancer cell killing without any prior antigen exposure or priming ([@B15], [@B24]--[@B26]). Although the γδ T cell proliferative function is impaired in patients with GBM, *ex vivo*-expanded/activated γδ T cells from healthy donors are highly cytotoxic to GBM tumor cells ([@B14]), suggesting a therapeutic effects of the adoptive transfer of Vγ9Vδ2 T-cells as an alternative immunotherapeutic strategy GBMs ([@B13], [@B19]). For example, temozolomide (TMZ)-induced DNA damage upregulates NKG2D ligands on cancer cells that are vulnerable to Vγ9Vδ2 T cell-mediated lysis in GBM ([@B27]).

Immune repertoire sequencing (IR-SEQ) can offer a comprehensive snapshot of the complexity and the diversity of the TCR repertoire ([@B28], [@B29]). There are many advantages of studying the TCRγδ repertoire compared with repertoires of TCRαβ and B-cell receptors because of relatively limited diversity of γδ T cells and their independence from different MHC haplotypes ([@B30]). In the blood, the repertoire of Vγ9Vδ2 T cells is skewed toward cells expressing a biased Vγ9 chain with Vγ9-JγP-C1 rearrangement, which involves Vγ9 gene segment, JγP (Jγ1.2) joining segment, and Cγ1 exon ([@B31], [@B32]). The Vγ9-JγP-C1 chain is paired mainly with Vδ2 chains ([@B31]). Despite using common V-(D)-J rearrangements, circulating Vγ9Vδ2 cells are still diverse due to the existence of D fragments, N-addition occurring during V-(D)-J recombination, and alternative rearrangement with the Cγ2 segment ([@B33], [@B34]). In this study, we analyzed GBM-infiltrating γδ T cells with unique repertoire diversity although γδ T cells may be important innate lymphocytes modulating GBM TME. To evaluate the identity of central nervous system (CNS)-resident γδ T cells and determine whether blood γδ T cells were recruited to the tumor or whether local CNS-resident γδ T cells responded to the tumor, we performed γδ TCR repertoire analyses using tumor tissue and matched peripheral blood from four patients with GBM based on IR-SEQ technology.

Materials and Methods {#s2}
=====================

Sample Collection and Preparation for Repertoire Sequencing
-----------------------------------------------------------

We recruited four cohorts of patients diagnosed with GBM. All patients signed informed consent for the use of patients\' samples for research purposes under protocols approved by the Samsung Medical Center Institutional Review Board (IRB no. 2016-11-073). Tumor tissues were stored in liquid nitrogen, and peripheral blood mononuclear cells (PBMCs) were isolated from whole blood with a Ficoll Histoplaque gradient. PBMCs were labeled with fluorescein isothiocyanate-conjugated anti-CD45 antibodies (347463; BD Biosciences, San Jose, CA, USA), and CD45^+^ cells were acquired using a BD FACS AriaIII flow cytometer with FACSDiva software (BD Biosciences).

Panel Sequencing Data Analysis
------------------------------

Samples were profiled using GliomaSCAN, a sequencing platform designed to target 312 genes specific for GBM, at the Samsung Medical Center. These target genes were chosen by literature mining or requested by the researchers and clinicians. The paired-end reads were aligned to the human reference genome (hg19) using Burrows-Wheeler Alignment tool (version 0.7.5). We converted sequence alignment and mapping (SAM) files into binary alignment and mapping (BAM) files using SAMtools (version 0.1.19) followed by reads sorting. Duplicated reads were removed from BAM files with Picard (version 1.128; <http://broadinstitute.github.io/picard>). Local realignment of reads around potential small indels and base quality score recalibration was performed with the Genome Analysis Toolkit (GATK, version 3.5.0) using dbSNP (build ID 137). Single nucleotide variants and indels were called using muTect2 (GATK version 3.8.0) and Strelka2 (version 2.8.2) with default parameter settings. The union of the variants identified by the two callers was used as the candidate variants. Variants were annotated using ANNOVAR. Variants located in exonic regions with a variant allele frequency of ≥ 0.1 were chosen for further investigation.

Whole-Transcriptome Sequencing (WTS) and Enumeration of Immune Cell Subsets From WTS
------------------------------------------------------------------------------------

Total RNA from human tissue was isolated with an RNeasy mini kit (\#74106; Qiagen, Hilden, Germany). The biospecimens used for this study were provided by Samsung Medical Center BioBank (IRB no. 2016-11-073). For all samples, RNA-Seq libraries were prepared from 500 ng total RNA using an Illumina TruSeq RNA Sample Prep kit. All libraries were sequenced to a read depth of more than 75 million reads using an Illumina HiSeq2000 instrument to generate paired reads ends with a total read length of 100 bp. After trimming poor-quality reads and adapter sequences from the FASTQ files for each sample, we aligned the reads to the human reference genome (hg19) using STAR (version 2.5.0i) with two pass default mapping mode ([@B35]). With the same reference genome used for mapping, gene annotation data obtained from Ensemble (v 74) were used to quantify aligned reads. Transcripts per million normalized values for each gene were calculated based on total gene read counts and the lengths of merged exons using RSEM (version 1.2.17) ([@B36]). *In silico* deconvolution analysis was performed with transcriptomic data using the CIBERSORT algorithm under the default mode ([@B37]). The proportions of 22 immune cell types, including seven T-cell types, naïve and memory B cells, plasma cells, NK cells, and myeloid subsets were estimated using LM 22 datasets, which included the public gene signature matrix of 547 genes to distinguish 22 leukocyte subsets.

Immune Cell Signature Analysis
------------------------------

Using curated immune gene expression signature (as shown in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}) ([@B38]--[@B41]), gene set variation analysis (GSVA) was implemented to calculate sample wise enrichment scores for each immune related gene set using the Bioconductor package 'GSVA' ([@B42]) based on the TMM normalized WTS data from four GBM samples used in this study and TCGA-GBM dataset. GSVA scores were scaled and plotted using heatmap.2 function from *ggplot2* ([@B43]). RPKM normalized RNA-seq datasets for 170 samples from TCGA were used for GSVA analysis. Interrelations of all possible pairs of GSVA scores of Immune signature and gene expression values of γδ T cell related genes were estimated from Pearson\'s correlation coefficient (*r*). To infer significance of each correlation, *P*-values were calculated based on asymptotic t approximation. Hierarchical clustering of immune signature gene sets (column) and γδ T cell related gene expressions (row) was performed via Pearson\'s correlation to measure distance with complete linkage algorithm for clustering distances.

Library Preparation and Sequencing
----------------------------------

The human TCRγ and TCRδ CDR3 regions were amplified using the commercially available iRepertoire platform (iRepertoire Inc., Huntsville, AL, USA) in LAS Inc. (Kimpo, Gyeonggi-do, Korea). Briefly, total RNA samples were subjected to reverse transcription polymerase chain reaction (PCR) using iR-PCR1 Rxn Mix (iRepertoire Inc.) and PCR1 Rxn Mix (iRepertoire Inc.). The PCR product was purified using PCR1 Rescue Mix (iRepertoire Inc.). A second PCR was then carried out using PCR2 Mix again and the product was purified using PCR2 Clean-up Mix (iRepertoire Inc.). Finally, quality and band size of libraries were assessed using an Agilent 2100 bioanalyzer (Agilent, Santa Clara, CA, USA). Libraries were quantified by quantitative PCR using CFX96 Real Time System (Bio-Rad, Hercules, CA, USA). After normalization, sequencing of the prepared library was conducted on the Miseq system (Illumina, San Diego, CA, USA) with 250-bp paired-end reads.

Analysis of the TCR Repertoire With High-Throughput Sequencing
--------------------------------------------------------------

Using an Illumina MiSeq system, we obtained 250-bp paired-end reads files, and the raw paired-end fastq files were analyzed using the Immune Repertoire High-throughput Sequence Analysis (IRSA) workflow at the iRepertoire website (<https://irweb.irepertoire.com/nir/>). The IRSA workflow included storing and managing sequencing data, removing sequencing artifacts, mapping reference sequences using the Smith-Waterman algorithm, identifying CDR3 junctions, and generating various distribution plots, such as domain usage, nucleotide nibbling, addition at the junction sites, and CDR3 length. Contigs of TCR constant genes were screened within quality control-filtered RNA-Seq data using the K-mer search algorithm of BBDuk program from the BBMap 35.74 suite (<http://sourceforge.net/projects/bbmap/>) with the parameter "k = 25 edist = 2". Constant genes for α-, β-, γ-, and δ-type TCRs used for the query were obtained from IMGT/LIGM-DB version 1.2.4 ([@B44]). Accession code [X02883](X02883) was used to retrieve the *TRAC* gene of TCRα; M12887 and L36092 for exons 1 and 2 of *TRBC1*; M12888 and L36092 for two exons of the *TRBC2* gene of TCRβ; M14996, M14997, and M14998 for three exons of *TRGC1*; M14002 for *TRGC2* of TCRγ; and M22149, M22150, and M22151 for three exons of *TRDC1* of TCRδ. Additionally, TCR Repertoire Utilities for Solid Tissue ([@B45]) was used to detect TCR sequences from RNA-Seq data for individual samples.

Immunohistochemistry (IHC)
--------------------------

IHC staining was performed using OpalTM 7-color manual kit (NEL81100KT, PerkinElmer, MA, USA) according to the manufacturer\'s protocol (2014;70:46-58). Briefly, the slides were deparaffinized in xylene and rehydrated in ethanol. Antigen retrieval was performed in tris-buffered saline buffer (pH 9.0) using microwave treatment (MWT). Using two antibodies are listed as follow: TCR gamma/delta antibody (2 μg/mL, mouse monoclonal, (5A6.E9), TCR1061, Thermofisher, MA, USA) and CD204 (1 μg/ml, rabbit polyclonal, ab64693, abcam, Cambridge, UK). These two antibodies were incubated 30 min in a humidified chamber at room temperature, followed by detection using the mouse/rabbit SuperPicture Polymer Detection HRP kit. Visualization of the primary antibody was accomplished using each Opal Fluorophore Working Solution (TSA, 1:100), after which the slide was placed in tris-buffered saline buffer (pH 9.0) and repeated using MWT. TCR gamma/delta and CD204 were visualized with opal 690 and 520, respectively. Nuclei were subsequently visualized with DAPI and the slide was coverslipped using the antifade mounting solution (ADI-950-260-0025, Enzo, NY, USA). The slides were examined with Vectra Polaris Automated Quantitative Pathology Imaging System (PerkinElmer). InForm image analysis software (PerkinElmer) was used to analyze the spectra for all fluorophores included from 420 to 720 nm.

Availability of Data and Material
---------------------------------

Newly generated GliomaSCAN, WTS, and γδ TCR repertoire-Seq data from this study can be accessed at the European Genome-phenome Archive with accession number [EGAS00001002790](EGAS00001002790).

Results {#s3}
=======

Clinical Presentation of Four Patients With Isocitrate Dehydrogenase (IDH) 1 Wild-Type GBM
------------------------------------------------------------------------------------------

The patients\' clinical course and therapeutic protocols are summarized in [Supplementary Figure 1](#SM1){ref-type="supplementary-material"} and [Table 1](#T1){ref-type="table"}. Confirmation of IDH1 wild-type, O^6^-methylguanine-DNA-methyltransferase (MGMT) promoter-unmethylated GBM was made using R132 sequencing and methylation-specific PCR according to the 2016 World Health Organization criteria ([@B46]) after gross total resection (GTR). Four cases of GBM showed different genetic mutations with no mutation in the *IDH1* gene ([Figure 1A](#F1){ref-type="fig"}). The first patient (case 1) was a 52-year-old woman with a large abnormal enhanced mass on the right temporal lobe on brain magnetic resonance imaging (MRI). She received concurrent chemoradiotherapy with TMZ followed by adjuvant TMZ (localized brain radiotherapy, total 60 Gy in 2 Gy per daily fraction with daily 75 mg/m^2^ TMZ over 6 weeks followed by adjuvant cycles of TMZ 150 mg/m^2^/day for 5 days during each 28-day cycle) ([@B47]), and brain MRI during four adjuvant TMZ courses revealed tumor recurrence around the resection site. For chemotherapy against recurrent GBM, she was treated with bevacizumab 10 mg/kg and irinotecan 125 mg/m^2^. The second patient (case 2) was a 70-year-old man suffering from left temporo-occipital GBM with MGMT promoter-unmethylation. The GTR of the primary tumor was confirmed on the post-operative follow-up brain MRI. After concurrent chemoradiation and two adjuvant TMZ courses, newly developed multifocal nodular enhancing lesions at the subependymal area of both lateral ventricles suggesting leptomeningeal seeding were found. Bevacizumab 10 mg/kg and irinotecan 125 mg/m were administered. The third patient (case 3) was a 60-year-old woman with a right temporal GBM with MGMT promoter-methylation. After GTR of the primary tumor was performed, she was treated with concurrent chemoradiotherapy with TMZ followed by adjuvant TMZ with no obvious disease relapse during the follow-up period of 10 months. Final fourth patient (case 4) had a left temporo-parietal GBM with MGMT promoter-methylation. She received standard concurrent chemoradiation plus adjuvant TMZ with no obvious disease relapse during the follow-up period of 14 months.

###### 

Clinical characteristics of four glioblastoma patients.

  **Case**   **Age**   **Gender**   **Tumor location**   **MGMT promoter methylation status**   **Post-adjuvant treatment**                                     **PFS (Days)**                              **OS (Days) (all censored)**
  ---------- --------- ------------ -------------------- -------------------------------------- --------------------------------------------------------------- ------------------------------------------- ------------------------------
  \#1        52        Female       Rt. T                Un-methylated                          Radiotherapy plus concomitant and adjuvant temozolomide         207 (progression during F/U)                270
  \#2        70        Male         Lt. T-O              Un-methylated                          Radiotherapy plus concomitant and adjuvant temozolomide (\#2)   144 (progression during F/U)                173
                                                                                                \+ Bevacizumab plus irinotecan after disease recurrence                                                     
  \#3        60        Female       Rt. T                Methylated                             Radiotherapy plus concomitant and adjuvant temozolomide         198 (Censored, no progression during F/U)   198
  \#4        61        Female       Lt. T-P              Methylated                             Radiotherapy plus concomitant and adjuvant temozolomide         249 (Censored, no progression during F/U)   249

*Lt., left; Rt., right; T-P, temporo-parietal; T, temporal; T-O, temporo-occipital; GTR, gross total resection; IDH1, Isocitrate dehydrogenase 1; WT, wild type; MGMT, O6-methylguanine-DNA-methyltransferase; RT, radiotherapy; TMZ, temozolomide; PFS, progression-free survival; OS, overall survival; F/U, follow-up*.

![Tumor-infiltrating γδ T cells and immune profiles in four GBM cases. **(A)** Summary of mutational changes in 21 GBM-related genes across sequenced samples. Red and blue denote single nucleotide variant events and indel events, respectively. **(B)** RPKM values (y-axis) of TCRB and TCRD captured reads from RNA-seq data of four cases (x-axis) are shown as a column chart. **(C)** The heatmap illustrates the z-score of normalized Gene Set Variable Analysis (GSVA) enrichment scores of a variety of curated immune gene signatures based on whole transcriptome sequencing data of four GBM samples analyzed in this study. The z-scores are calculated based on average and standard deviation of GSVA enrichment scores of each patient, indicating relative enrichment scores of immune gene sets within each patient. The scale of z-score is shown: red illustrates high enrichment and blue illustrates low enrichment. **(D)** The representative images of the multiplex immunohistochemistry analysis of four GBM patient tissue samples stained for γδ TCR in red and CD204 in green. Scale bar, 50 μm.](fimmu-10-00555-g0001){#F1}

Abundant Infiltration of Macrophages and Innate and Effector/Memory Lymphocytes in GBM Tumor Tissues
----------------------------------------------------------------------------------------------------

To estimate antitumor immunity in GBM pathogenesis, we obtained gene expression profiles of four GBM tissues and measured the relative proportions of various immune cells through *in silico* deconvolution analysis **(**CIBERSORT; see [Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). In all four cases, heavy infiltration of macrophages (32.0--80.3% of all immune cells), particularly M2 macrophages, and mast cells (6.7--34.6% of all immune cells) was noted. T and NK cells constituted about 5.6--31.0% of all immune cells, and most tumor-infiltrating lymphocytes (TILs) were innate and effector/memory cells, whereas naïve T cells were scarce. However, the enumeration of tumor-infiltrating γδ T cells via the CIBERSORT algorithm was difficult since γδ T cells also express most genes expressed in αβ T cells and NK cells ([@B37], [@B48]). Alternatively, the ratios of γδ T to αβ T cells were calculated to be around 0.8--1.1 by measuring the reads per kilobase of transcript per million mapped reads (RPKM) values of the *Tcrd* and *Tcrb* constant regions, suggesting that the ratios of γδ T cells were equal to or even higher than those of αβ T cells in the tumor tissues ([Figure 1B](#F1){ref-type="fig"}). The case 3 showed the highest ratio of γδ T cells than the other cases, whereas the case 4 showed a lower ratio of γδ T cells than other cases.

To explore the effects of γδ T cell infiltration, the phenotype of immune cells within the TME in four GBM samples was then analyzed based on multiple gene sets curated from various sources (summarized in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}). In all four cases, heterogeneous and complex activation status of specific tumor-associated immune subsets modulating pro- or anti-tumor activity was demonstrated in each case. Notably, a relatively high abundance of cytotoxic T cell and Th1 genes was detected in case 3, which showed the highest ratio of γδ T cells over αβ T cells ([Figure 1C](#F1){ref-type="fig"}). In contrast, case 4 tumor samples highly expressed Th17 and exhausted T cell genes compared to other samples. In case 1, genes related to M2 macrophage, Treg and exhausted T cells shaping immune-suppressive TME were relatively upregulated ([Figure 1C](#F1){ref-type="fig"}). In further IHC study by using deparaffinized section slides, γδ T cells and TAMs were abundantly distributed throughout the tumor in all four cases and γδ T cells and macrophages were closely associated ([Figure 1D](#F1){ref-type="fig"}).

We presumed that the abundance of γδ T cells may be correlated with TME, but we could not draw clear conclusion due to small sample sizes. To overcome this limitation, we further examined patient populations from the published dataset from TCGA RNA-seq (*N* = 170) ([Figure 2](#F2){ref-type="fig"}). Interestingly, the gene signature score of γδ T cells more positively correlated with those of M1 macrophages and Th1 cells than those of M2 macrophages and Th2 cells, respectively. Notably, the γδ T cell activity was strongly associated with cytotoxic T cell activity, suggesting that GBM-infiltrating γδ T cells contribute to anti-tumoral immunity. However, the γδ T cell activity was also associated with the activities of exhausted and regulatory T cells. These findings are consistent with previous findings demonstrating that γδ T cells show a high degree of plasticity and are able to assume different phenotypes, including Th1-like, Th2-like, Th17-like, follicular Th-like, or Treg-like characteristics, depending on the cytokine milieu in surrounding microenvironment ([@B49]--[@B55]). Based on the hypothesis that the γδ T cells could be responsible for the polarization of TAMs, we performed repertoire analyses of γδ T cells since individual subsets of γδ T cells with specific variable domains of γ or δ chains have unique functions in local environments.

![Correlation patterns of Gene Set Variable Analysis (GSVA) enrichment scores of a variety of curated immune gene signatures for 170 GBM patients from TCGA database. **(A)** A clustered heatmap of Pearson\'s correlation coefficient of GSVA scores over all immune signature gene sets. Hierarchical clustering was performed based on Pearson\'s correlation distance with ward linkage method. Dark orange denotes high correlation (*r* = 1) while dark blue denotes a lack of correlation (*r* \> 0). **(B)** The diagonal of the chart represent distribution of GSVA enrichment scores. The bivariate scatter plots of linear regression fits of each pairs with the fitted lines are shown on the bottom of the diagonal. Pearson\'s correlation coefficient values with the level of significance were shown on the top of the diagonal. ^\*\*\*^*P* \< 0.001.](fimmu-10-00555-g0002){#F2}

Predominant Infiltration of Vγ9Vδ2 T Cells in GBM Tumor Tissues
---------------------------------------------------------------

To compare γδ TCR repertoires between tumor-infiltrating and blood γδ T cells and among γδ T cells from four patients, we generated and amplified *Tcrg* and *Tcrd* cDNA libraries from tumor tissues and sorted (2 × 10^5^ to 8 × 10^6^) blood CD3^+^ cells from four patients. The libraries, which could be distinguished by barcodes, were then pooled and sequenced (Illumina MiSeq). In total, 159,138--2,483,772 total clean nucleotide sequences (CNTs) and about 141--1,157 unique clean nucleotide sequences (CNUs) from the tumor samples and 402,922--2,145,312 CNTs and 93--2,709 unique CNUs from the sorted blood CD3^+^ cells were analyzed in this study ([Table 2](#T2){ref-type="table"}). The *TCRG* and *TCRD* tree maps for each γδ T cell population showed that intratumoral γδ T cells expressed less diverse CDR3 nucleotide sequences for the *TCRG* and *TCRD* genes than blood γδ T cells, except in case 3 ([Figures 3A,B](#F3){ref-type="fig"}). Case 3 showed oligoclonal γδ T cells in both blood and tumor tissue. The calculation of Shannon indices, which reflected both richness and evenness of the CDR3 clonotypes, showed that the repertoires of *TCRG* and *TCRD* CDR3 sequences were very restricted in case 3 and that the intratumoral γδ T cells were less diverse than blood γδ T cells ([Table 2](#T2){ref-type="table"}). In all cases, the most abundant γδ T cells were of Vγ9 and Vδ2 cells.

###### 

γδ T cell receptor repertoire diversity indices.

  **Case \#**   **TCR chain**   **Cell origin**   **Shannon index**   **Janssen-Shannon divergence**
  ------------- --------------- ----------------- ------------------- --------------------------------
  \#1           γ chain         PBMCs             6.841               0.738
                                Cancer tissue     6.087               
                δ chain         PBMCs             7.599               0.802
                                Cancer tissue     5.156               
  \#2           γ chain         PBMCs             5.665               0.543
                                Cancer tissue     4.736               
                δ chain         PBMCs             6.069               0.560
                                Cancer tissue     4.467               
  \#3           γ chain         PBMCs             1.458               1
                                Cancer tissue     3.270               
                δ chain         PBMCs             0.624               0.999
                                Cancer tissue     0.661               
  \#4           γ chain         PBMCs             5.301               0.795
                                Cancer tissue     4.609               
                δ chain         PBMCs             3.612               0.771
                                Cancer tissue     2.905               

![T cell receptor γ and δ chain CDR3 tree map plots for blood and GBM tumor tissue γδ T cells and the relative proportions of individual TCR TCR Vγ or Vδ gene segments. **(A)** for TCRγ **(B)** for TCRδ. CDR3 tree-map plots illustrate the unique TCRγ or TCRδ CDR3 nucleotide sequences obtained from given samples of four GBM patients. Each rectangle in a given tree-map represents a unique CDR3 sequence, and the size of each rectangle indicates the relative frequency of an individual sequence. The colors for the individual CDR3 sequences in each tree-map plot were chosen randomly. Bottom graphs in **(A,B)** show the percentages of use of each TCR Vγ **(A)** or Vδ **(B)** domain in PBMCs (white) or cancer tissues (black) from each patient.](fimmu-10-00555-g0003){#F3}

Unique Vγ9Jγ2-Vδ2 T Cells Were Distinctively Found in GBM Tumor Tissues, but Not in Blood
-----------------------------------------------------------------------------------------

Vγ9Vδ2 T cells are known to be the most abundant type of adult blood γδ T cells ([@B56]). These cells undergo rapid expansion within the first year of life ([@B57]). Because Vγ9Vδ2 T cells are strongly activated by bacteria-derived pAgs ([@B18], [@B21]), these cells appear to be expanded by commensal bacteria ([@B18]). A few previous TCR repertoire analyses have revealed the predominance of canonical Vγ9JγP sequences ([@B58]). Although intratumoral and blood Vγ9Vδ2 T cells were apparently similar, the Jensen-Shannon divergence (JSD) indices, a measure of repertoire comparison ([@B59]), showed remarkable distinctness of intratumoral γδ T cells from blood γδ T cells ([Table 2](#T2){ref-type="table"}). Notably, in case 3, intratumoral γδ T cells were completely distinct from blood γδ T cells (JSD = 1 indicates complete divergence of two repertoires). When we plotted the clonotypes based on Vγ and Jγ segments, the absolute or relative abundance of Vγ9Jγ2 sequences was prominent in intratumoral γδ T cells, except in case 4 ([Figure 4](#F4){ref-type="fig"}). The canonical Vγ9JγP sequences were the most abundant sequences in blood γδ T cells, except in case 4. Case 4 was unique in that many non-canonical Vγ9Jγ1, Vγ9Jγ2, Vγ9JγP1, and Vγ9JγP2 sequences as well as the canonical Vγ9JγP sequences were found in blood γδ T cells, as was verified through repetitive sequencing analysis. Paradoxically, the canonical Vγ9JγP sequences were the most abundant in intratumoral γδ T cells from case 4. Collectively, the non-canonical Vγ9Jγ2-Vδ2 T cells were distinctively observed in intratumoral γδ T cells in three of four 4 GBM cases.

![The relative proportion of each combination of Vγ and Jγ segments in γδ T cells in blood and GBM tumor tissue samples of four patients. 3D graphs show the relative percentages of combinations of Vγ-Jγ usages in PBMCs or GBM tumor tissues from four patients.](fimmu-10-00555-g0004){#F4}

Unique CDR3 Vγ9Jγ2 and Vγ9JγP Clonotypes From GBM Tumor Tissues and Blood
-------------------------------------------------------------------------

To date, it is unclear whether there were variations in TCR Vγ9 γ chains related to antigenic specificity. In this study, we attempted to identify shared clonotypes that were found in different samples, although the antigenic specificity could not be deduced from the sequences. We reasoned that clonotypes of tumor phospho-antigen-specific Vγ9Vδ2 T cells may be different from blood bacterial phospho-antigen-specific Vγ9Vδ2 T cells. We listed the top 10 CDR3 clonotypes of canonical Vγ9JγP or non-canonical Vγ9Jγ2 sequences from four blood and tumor samples ([Table 3](#T3){ref-type="table"}). We found that the Vγ9JγP CDR3 clonotype ALWEVQELGKKIKV was the most frequent clonotype in blood and tumor samples from three cases, suggesting that this was the most representative clonotype of canonical Vγ9JγP γ chains. However, other frequent Vγ9JγP γ chain CDR3 clonotypes were also found, such as ALWEPPQELGKKIKV, in both blood and tumor samples from only case 1, ALWEKQELGKKIKV in the blood sample from case 2, and ALWEALRLGKKIKV in blood and tumor samples from case 3. Notably, we found several frequent Vγ9Jγ2 γ chain CDR3 clonotypes that were unique to tumors and were not found in blood. The representative Vγ9Jγ2 γ chain clonotypes included ALWEGLKKL in case 1, ALWEVQYKKL in case 2, ASKKTKKL in case 3, and ALWEVRYYYKKL in case 4. In case 2, ALWESSNYYKKL was a Vγ9Jγ2 γ chain clonotype found only in the blood. Collectively, we could discern unique blood- and tumor-specific Vγ9 γ chain CDR3 clonotypes and found that many tumor-specific clonotypes were of Vγ9Jγ2 γ chains, and many blood-specific clonotypes were of Vγ9JγP γ chains. In particular, the Vγ9JγP CDR3 clonotype ALWEVQELGKKIKV appeared to be the most representative Vγ9JγP γ chains. The γδ T cells with this clonotype appeared to be recruited to the tumor tissues from the blood.

###### 

TOP 10 CDR3 sequence by the usage proportion of Vγ9Jγ2 or Vγ9JγP in patient blood and tissue sample.

  **CASE \#1**   **PBMCs**                      **Tissue**                                                                                                        
  -------------- ------------------------------ --------------------------- -------------------------- ------------------------------ --------------------------- --------------------------
  1              ALWARLYYKKL                    17.86                       1.96                       ALWEVRYYYKKL                   27.19                       12.09
  2              ALWEVQPPYYKKL                  5.47                        0.60                       ALWARLYYKKL                    12.03                       5.35
  3              ALWEVSLYKKL                    5.32                        0.58                       ALWECHYYKKL                    6.81                        3.03
  4              ALWEVAPLYKKL                   4.82                        0.53                       ALWEGNYYKKL                    3.92                        1.74
  5              ALWESPYYKKL                    4.35                        0.48                       ALWEAPKNTL                     3.61                        1.60
  6              ALARKKL                        4.31                        0.47                       ALWEGVNYYKKL                   3.51                        1.56
  7              ALWEVLRYKKL                    4.29                        0.47                       ALWEVQF                        3.43                        1.52
  8              ALWDKKL                        4.25                        0.47                       ALWEVLLEKL                     3.24                        1.44
  9              ALWNKKL                        4.20                        0.46                       ALWEVPYYKKL                    2.86                        1.27
  10             ALWEVRAWVYYKKL                 4.17                        0.46                       ALWVYKKL                       2.85                        1.27
  **Vγ9 JγP**    **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**
  1              ALWEVQELGKKIKV                 17.76                       12.83                      ALWEVQELGKKIKV                 5.14                        5.14
  2              ALWEVRELGKKIKV                 5.31                        3.83                       ALWEVRELGKKIKV                 3.83                        3.83
  3              ALWEVQRELGKKIKV                3.04                        2.20                       ALWEDQELGKKIKV                 2.16                        2.16
  4              ALWEPLGELGKKIKV                2.75                        1.98                       ALWDKQELGKKIKV                 1.57                        1.57
  5              ALWEELGKKIKV                   2.71                        1.96                       ALWVVELGKKIKV                  1.43                        1.43
  6              ALWEAQELGKKIKV                 2.68                        1.93                       ALWEVMELGKKIKV                 1.36                        1.36
  7              ALWEVQGLGKKIKV                 2.49                        1.80                       ALWEPPELGKKIKV                 1.35                        1.35
  8              ALWEEKELGKKIKV                 2.30                        1.66                       ALWAVELGKKIKV                  1.25                        1.25
  9              ALWDKQELGKKIKV                 2.26                        1.63                       ALLGKKIKV                      1.18                        1.18
  10             ALWEVRRELGKKIKV                2.21                        1.59                       ALWEVNQELGKKIKV                1.09                        1.09
  **CASE \#2**   **PBMCs**                      **Tissue**                                                                                                        
  **Vγ9 Jγ2**    **CDR3 amino acid sequence**   **% of Vγ9Jγ2 sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9Jγ2 sequences**   **% of total sequences**
  1              ALWEAPVEKL                     26.04                       0.37                       ALWEGLKKL                      17.58                       2.95
  2              ALSMQSFGYKKL                   16.47                       0.23                       AFENYYKKL                      17.07                       2.87
  3              ALWEGPKKL                      16.19                       0.23                       ALEDKL                         15.50                       2.60
  4              ALWEEDPDYKKL                   13.80                       0.19                       ALWEVYV                        15.35                       2.58
  5              ALWEVPAGYKKL                   12.40                       0.17                       ALWEVLYYKKL                    13.62                       2.29
  6              ALWEVRDYYKKL                   6.69                        0.09                       ALSNYKKL                       13.32                       2.24
  7              ALWRIYYKKL                     4.15                        0.06                       ALWEFLYWGKL                    5.38                        0.90
  8              ALGGGKL                        3.60                        0.05                       ALEDKF                         0.66                        0.11
  9              ALWEASVEKL                     0.15                        0.00                       ALGDKL                         0.47                        0.08
  10             ALGGGKF                        0.13                        0.00                       ALEDRL                         0.15                        0.03
  **Vγ9 JγP**    **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**
  1              ALWEPPQELGKKIKV                22.95                       18.42                      ALWEPPQELGKKIKV                31.41                       20.52
  2              ALWEYRQELGKKIKV                8.59                        6.89                       ALWERELGKKIKV                  9.49                        6.20
  3              ALWEVQELGKKIKV                 8.34                        6.70                       ALWEVEELGKKIKV                 8.13                        5.31
  4              ALWEAQELGKKIKV                 7.64                        6.13                       ALWEVQELGKKIKV                 7.65                        4.99
  5              ALWEVEELGKKIKV                 6.15                        4.94                       ALWEPQELGKKIKV                 6.75                        4.41
  6              ALWEPQELGKKIKV                 5.70                        4.58                       ALWEDNSPKLGKKIKV               4.50                        2.94
  7              ALWELLEQELGKKIKV               4.91                        3.94                       ALWERQELGKKIKV                 4.25                        2.78
  8              ALWEVPRELGKKIKV                3.68                        2.95                       ALWAQELGKKIKV                  4.05                        2.65
  9              ALWEGEQELGKKIKV                2.88                        2.32                       ALWELLEQELGKKIKV               4.03                        2.64
  10             ALWEVQEELGKKIKV                2.50                        2.01                       ALWEGRELGKKIKV                 4.03                        2.63
  **CASE \#3**   **PBMCs**                      **Tissue**                                                                                                        
  **Vγ9 Jγ2**    **CDR3 amino acid sequence**   **% of Vγ9Jγ2 sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9Jγ2 sequences**   **% of total sequences**
  1              ALWESSNYYKKL                   98.22                       42.79                      ALWEVQYKKL                     55.75                       29.18
  2              ALWEPSNYYKKL                   0.44                        0.19                       ALWEHYYKKL                     31.20                       16.33
  3              ALWGSSNYYKKL                   0.33                        0.14                       ALWEVREKL                      12.08                       6.32
  4              ALWESSSYYKKL                   0.26                        0.11                       ALWGHYYKKL                     0.21                        0.11
  5              ALWESPNYYKKL                   0.21                        0.09                       ALWEVREEL                      0.18                        0.10
  6              ALCESSNYYKKL                   0.21                        0.09                       ALWEVQHKKL                     0.10                        0.05
  7              ALWESSDYYKKL                   0.15                        0.07                       ALWEYYYKKL                     0.08                        0.04
  8              ALWKSSNYYKKL                   0.07                        0.03                       ALWEHHYKKL                     0.07                        0.04
  9              ALWVSSNYYKKL                   0.04                        0.02                       ALWEVQCKKL                     0.07                        0.04
  10             ALWESSYYYKKL                   0.01                        0.01                       ALWEMQYKKL                     0.04                        0.02
  **Vγ9 JγP**    **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**
  1              ALWEKQELGKKIKV                 98.65                       49.31                      ALWAQELGKKIKV                  96.51                       6.89
  2              ALWEEQELGKKIKV                 0.34                        0.17                       ALGAQELGKKIKV                  2.17                        0.15
  3              ALWGKQELGKKIKV                 0.26                        0.13                       ALWAQGLGKKIKV                  0.37                        0.03
  4              ALWERQELGKKIKV                 0.26                        0.13                       ALWARELGKKIKV                  0.27                        0.02
  5              ALWEKRELGKKIKV                 0.23                        0.12                       ALRAQELGKKIKV                  0.24                        0.02
  6              ALWEKQKLGKKIKV                 0.05                        0.03                       ALWTQELGKKIKV                  0.21                        0.02
  7              ALWKKQELGKKIKV                 0.05                        0.03                       ALWAQVLGKKIKV                  0.08                        0.01
  8              ALWVKQELGKKIKV                 0.03                        0.01                       ALWPQELGKKIKV                  0.06                        0.00
  9              ALWEKHELGKKIKV                 0.02                        0.01                       ALWAQKLGKKIKV                  0.05                        0.00
  10             ALCEKQELGKKIKV                 0.02                        0.01                       ALWAQEVGKKIKV                  0.04                        0.00
  **CASE \#4**   **PBMCs**                      **Tissue**                                                                                                        
  **Vγ9 Jγ2**    **CDR3 amino acid sequence**   **% of Vγ9Jγ2 sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9Jγ2 sequences**   **% of total sequences**
  1              ALWEVQLPNYYKKL                 24.75                       2.56                       ASKKTKKL                       14.06                       1.53
  2              ALWEKSKNYYKKL                  17.20                       1.78                       ALWEGENYYKKL                   9.58                        1.04
  3              ALWEVLYKKL                     7.02                        0.73                       ALWEVWRKL                      6.03                        0.66
  4              ALWEVMDYKKL                    4.23                        0.44                       ALWGRNYYKKL                    5.07                        0.55
  5              ALWESEVISNYYKKL                4.10                        0.42                       ALWEVRFYYKKL                   4.73                        0.52
  6              ALWEVMNKKL                     3.92                        0.40                       ALWEVLLNYYKKL                  4.63                        0.50
  7              ACYYKKL                        3.71                        0.38                       ALWEVPDYYKKL                   4.11                        0.45
  8              ALWEVPEKL                      3.34                        0.35                       ALWEVDYKKL                     4.09                        0.44
  9              ALWEAGNYYKKL                   3.12                        0.32                       ALWETVKKL                      4.07                        0.44
  10             ALWDVRL                        2.81                        0.29                       ALWEDLGKL                      3.79                        0.41
  **Vγ9 JγP**    **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**   **CDR3 amino acid sequence**   **% of Vγ9JγP sequences**   **% of total sequences**
  1              ALWEALRLGKKIKV                 31.84                       3.81                       ALWESQELGKKIKV                 44.74                       30.35
  2              ALWEVQELGKKIKV                 13.09                       1.57                       ALWDSYGLGKKIKV                 15.55                       10.55
  3              ALWEQELGKKIKV                  13.04                       1.56                       ALWEVQELGKKIKV                 14.28                       9.69
  4              ALWGQELGKKIKV                  5.92                        0.71                       ALWGQELGKKIKV                  9.58                        6.50
  5              ALWGSELGKKIKV                  5.12                        0.61                       ALWEVQGELGKKIKV                8.13                        5.51
  6              ALWESQELGKKIKV                 4.92                        0.59                       ALWEQELGKKIKV                  3.94                        2.67
  7              ALQELGKKIKV                    4.81                        0.58                       ALWEIFQELGKKIKV                1.16                        0.79
  8              ALWEVQGELGKKIKV                4.45                        0.53                       ALWETQELGKKIKV                 1.10                        0.75
  9              ALWEIFQELGKKIKV                4.28                        0.51                       ALWEVFELGKKIKV                 0.58                        0.40
  10             ALWDSYGLGKKIKV                 2.28                        0.27                       ALWEVGELGKKIKV                 0.36                        0.24

Discussion {#s4}
==========

In this study, we investigated the γδ TCR repertoires in tumor tissues and matched blood from four patients with IDH1 wild-type GBM. Except in one case, unique tumor-infiltrating GBM-specific γδ T cells used Vγ9Jγ2 sequences whereas blood γδ T cells were dominated by γδ T cells with Vγ9JγP sequences. Based on the TCRγ gene structure, Vγ9Vδ2 T cells with Vγ9Jγ2 sequences should use the Cγ2 segment, whereas canonical γδ T cells with Vγ9JγP sequences found predominantly in the blood are presumed to be Cγ1 users as the JγP segment is much closer to the Cγ1 segment than to the Cγ2 segment. Because γδ T cells developed sequentially from Cγ1-dependent proximal rearrangement to Cγ2-dependent distal rearrangement ([@B32], [@B60]), these two types of Vγ9Vδ2 T cells appear to have developed in different developmental stages.

Upon antigen stimulation, γδ T cells differentiate into two major types of memory T cells: central memory cells, which patrol the blood and secondary lymphoid organs, and effector memory cells, which migrate to peripheral tissues ([@B52]). The circulating Vγ9Vδ2 T cells preferentially express inflammatory homing chemokine receptors including CC chemokine receptor (CCR)1, CCR5, CCR8, CXCR3, and C-X-C chemokine receptor type 4 (CXCR4), which are involved in cell migration from the bloodstream to the tumor site, where they display broad and potent antitumoral activity ([@B61]--[@B64]). Then, activated Vγ9Vδ2 T cells are able to secrete chemokines, such as chemokine ligands (CCL)3, CCL4, chemokine (C-X-C motif) ligand (CXCL)10, and CXCL13, to recruit dendritic cells/macrophages, NK cells, αβ T cells and B cells to the tumor site ([@B53], [@B65]). Vγ9Vδ2 T cells can directly kill tumor cells through the secretion of cytolytic molecules or antibody-dependent cell-mediated cytotoxicity or indirectly prime and modulate immunological functions of other innate and adaptive immune cells leading to the establishment of profound antitumor immunity ([@B53], [@B66], [@B67]). For example, upon pAg stimulation, Vγ9Vδ2 T cells preferentially differentiate into Th1-like cells with profound interferon-γ and tumor necrosis factor-α responses ([@B49], [@B54]). However, upon stimulation with IPP, Vγ9Vδ2 T cells can also be polarized into Th2-like cells, which are characterized by increased secretion of interleukin (IL)-4 upon stimulation with IL-4 and anti-IL-12 antibodies ([@B54]) and Treg-like γδ-T cells with regulatory/immunosuppressive functions in the presence of IL-15 and transforming growth factor-β ([@B55]), displaying the functions for promoting tumor development through direct or indirect strategies. To date, it is not known whether these pro-tumor Vγ9Vδ2 T cells have the same clonotypes as antitumor Vγ9Vδ2 T cells. Classical immunotherapeutic approaches to GBM have shown mixed results, and therapies focused on innate lymphocyte activity against GBM have not been rigorously evaluated. The adoption of Vγ9Vδ2 T cells with both canonical and non-canonical Vγ9Vδ2 T cells needs to be evaluated in GBM immunotherapy.

The binding between canonical Vγ9Vδ2 TCR and pAgs presented by BTN3A1 leads to activation of Vγ9Vδ2 T cells ([@B18], [@B21]). Microbe-derived hydroxymethyl-but-2-enyl-pyrophosphate (HMBPP) is \~10,000-fold more potent than cancer cell-derived IPP in the activation of Vγ9Vδ2 T cells ([@B18]), but it is not understood how HMBPP triggers stronger signaling in Vγ9Vδ2 T cells than IPP. CDR3γ appeared to be essential for recognition of pyrophosphate-containing metabolites by BTN3A1. In particular, Lys109 in the CDR3γ from the JγP segment was shown to be critical for the binding ([@B68]). The CDR3γ sequences from Vγ9Jγ2-Vδ2 T cells showed a shorter length than the CDR3γ sequences from canonical Vγ9Vδ2 T cells with Vγ9JγP sequences, and some clonotypes from Vγ9Vδ2 T cells with Vγ9Jγ2 sequences lacked the critical Lys residue ([Supplementary Figure 3](#SM1){ref-type="supplementary-material"}). Therefore, further studies are needed to determine whether intratumoral Vγ9Jγ2-Vδ2 T cells recognize the same antigens that bind to the canonical Vγ9Vδ2 T cells with Vγ9JγP sequences with similar affinities.

Collectively, our data showed that the TCR repertoires of intratumoral γδ T cells were clearly distinct from those of blood γδ T cells when comparing TCR repertoires from four patients with GBM. We also identified several GBM-specific Vγ9Jγ2-Vδ2 T cells that were not found in the blood. In-depth investigation of their antigenic specificities and anti- or protumor differentiation potentials through interaction with tumor cells and other stromal cells within GBM-specific TME should be performed to improve our understanding of the roles of γδ T cells in the establishment of the TME and to apply them for the future immunotherapies against GBMs refractory to conventional immunotherapies.
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